>latest-news

Upperton Pharma Boosts Capacity After Nottingham Site Secures MHRA Nod

Upperton's new Nottingham facility gets MHRA approval, boosting GMP manufacturing capabilities.

Breaking News

  • Jul 17, 2024

  • Mrudula Kulkarni

Upperton Pharma Boosts Capacity After Nottingham Site Secures MHRA Nod

Upperton Pharma Solutions celebrates a major milestone with the successful MHRA inspection of its new 50,000 sq ft development and GMP manufacturing facility in Nottingham, UK. The UK Government's regulatory authority's approval underscores Upperton's achievement in swiftly completing the facility's construction, commissioning, validation, and approval within just 18 months. This accomplishment expands Upperton's capabilities to support the development of oral, nasal, and pulmonary drug products, alongside providing Phase I, II, and III clinical supplies.

Nikki Whitfield, CEO of Upperton Pharma Solutions, said in a statement, “We are absolutely delighted to achieve this milestone. We have been conducting manufacturing scale-up activities since the start of the year following the installation of the larger-scale solid oral dosage form process trains and this gives the green light for our GMP facility to support clients right through to late-phase clinical manufacture and product registration”.

The MHRA's successful inspection empowers Upperton Pharma Solutions to consolidate its R&D, GMP manufacturing, and commercialization efforts at a single site. Recent investments in advanced process equipment, including the Gerteis Mini-Pactor®, GEA Post Hoist Blender, O’Hara M50 Tablet Coating System, and ZANASI 40 Capsule Filler, position Upperton to handle batch sizes up to 250kg and a diverse range of dosage forms. This capability spans solids, liquids, semi-solids, nasal and inhaled pharmaceuticals, covering potent molecules and controlled drugs. The MHRA approval marks a pivotal step in Upperton's evolution into an integrated CDMO.

Paul Kelsall, Director of Clinical Manufacturing, commented, “This is a dedication to the tremendous hard work our colleagues have put in to achieve the targets and aspirations of our business. We are looking forward to working with our clients and offering services from early-stage development through to late-stage clinical manufacture and Product Registration. These are exciting times for Upperton as we continue to move forward and expand our capabilities.”

Jon Austwick, Director of Quality & Compliance, further added  “This achievement is a culmination of 18 months of hard work to commission a state-of-the-art facility and build the rigorous quality and compliance processes to ensure the highest standards of service to our customers.”

 

Ad
Advertisement